Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.
Roche & Zealand Pharma join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. See why this ...